I specialize in sarcomas, which are cancers of connective tissues (such as bones, muscles and tendons). I coordinate the evaluation of patients with sarcomas, supervise their chemotherapy and coordinate their treatment with surgeons, radiation oncologists and other specialists. I am the senior member of our sarcoma team, which has three physicians and a nurse practitioner.
When dealing with complicated diseases like sarcomas, it is important to take the time to do things right. Treating sarcomas involves lots of scans, tests, medicines and consultations with other professionals -- and families can find the process confusing and overwhelming. Many sarcoma patients are teenagers who are just beginning to gain their freedom, only to lose a lot of it as they become cancer patients. That is why it is important that I understand the patient and family, and that they understand what we are doing and why. We work to make the patient and family active participants in treatment.
I also specialize in medication and chemotherapy safety. Working closely with other physicians, nurses, pharmacists, computer specialists and others, I try to make the complex process of ordering and administering chemotherapy and other medicines as straightforward and safe as possible, both in the Cancer Center and in the hospital as a whole.
My research involves the development of sarcoma studies through the Children's Oncology Group, the world's largest childhood cancer research organization. I also work with biology researchers who are trying to combine clinical and biologic data to understand and treat sarcomas better.
At The Children's Hospital of Philadelphia, we are fortunate to have people who study every variety of pediatric cancer in depth. Whether it's sarcoma or another cancer, there is someone in our division who is an expert and focuses their research on it -- and who knows other experts around the world. We also have nurses, child life specialists, nutritionists, social workers, physical therapists and others who specialize in treating children with cancer. That is a huge advantage for patients and families, and helps make CHOP a wonderful place to work.
Education and Training
MD - University of Rochester School of Medicine, Rochester NY
Pediatrics - University of Virginia Hospital, Charlottesville, VA
Pediatrics - Hospital for Sick Children, London, England
Pediatrics - University of Virginia Hospital, Charlottesville, VA
Leukaemia Research Fellow - Institute of Child Health, London, UK
Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
Honorary Senior Registrar - Hospital for Sick Children, Great Ormond Street, London, UK
Hematology-OncologyPediatrics – American Board of Pediatrics
Titles and Academic Titles
Medical Director, Tumor Registry, Cancer Center
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Clinical and "translational" research on the diagnosis and treatment of childhood sarcomas
System improvement for medical safety
Lerman DJ, Monument MJ, McIlvaine E, Liu X-Q, Huang D, Monovich L, Beeler N, Gorlick RG, Marina NM, Womer RB, Bridge JA, Krailo MD, Randall RL, Lessnick SL: Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group. Pediatric Blood and Cancer 62:759-65, 2015.
DuBois S, Krailo M, Gebhardt M, Donaldson S, Marcus K, Dormans J, Shamberger R, Sailer S, Nicholas R, Healey J, Tarbell N, Randall RL, Devidas M, Meyer J, Granowetter L, Womer RB, Bernstein M, Marina N, Grier HE: Comparative Evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children’s Oncology Group. Cancer. 2015 Feb 1;121(3):467-75.
Volchenboum S, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER: Gene expression profiling of Ewing sarcoma tumors reveals the prognostic importance of tumor-stromal interactions. Journal of Pathology. J Pathol Clin Res. 2015 Apr;1(2):83-94.
Monument MJ, Johnson KM, McIlvaine E, Watkins WS, Jorde LB, Womer RB, Bridge JA, Schiffman JD, Krailo MD, Randall RL, Lessnick SL: Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLOS ONE 9:e104378, 2014.
Sacks N, Hwang W-T, Lange BJ, Tan K-S, Sandler ES, Rogers PC, Womer RB, Pietsch JB, Rheingold SR: Proactive enteral tube feeding in pediatric patients undergoing chemotherapy. Pediatric Blood and Cancer, 61:281-285, 2014.
Hill-Kayser CE, Tochner Z, Both S, Lustig R, Reilly A, Balamuth NJ, Womer RB, Maris JM, Grupp S, Bagatell R: Proton versus photon radiation therapy for patients with high-risk neuroblastoma: The need for a customized approach. Pediatric Blood and Cancer 60:1606-1611, 2013.
Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, Wolden SL, Parham DM, Rodeberg DA, Kao SC, Womer RB: Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: A report from the Children’s Oncology Group. Journal of Clinical Oncology 31:3226-3232, 2013.
Shapiro B, Womer RB: Rhabdomyosarcoma. In: Decision Making in Oncology, Philip Schein (ed), BC Decker, Inc., Philadelphia, 1989, pp. 198-99.
Cornelius AS, Womer RB: Osteosarcoma. In: Decision Making in Oncology, Philip Schein (ed), BC Decker, Inc., Philadelphia,1989, pp. 202-203.
Womer RB: Extracranial Primitive Neuroectodermal Tumor: Proceedings of the Tumor Board of the Children's Hospital of Philadelphia. Medical and Pediatric Oncology 12(2):119-122, 1984.
Posters and Presentations
Cash T, McIlvaine E, Krailo MD, Lessnick S, Lawlor ER, Laack N, Sorger J, Marina N, Grier HE, Granowetter L, Womer RB, DuBois SG: Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal Ewing sarcoma: A report from the Children’s Oncology Group. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2015.
Daw NC, Laack NN, Krailo MD, McIlvaine E, Grier HE, Granowetter L, Womer RB, Marina NM, Bernstein ML, Gorlick RG, Randall L: Local control modality and outcome in Ewing sarcoma of the femur: A report from the Children’s Oncology Group. Connective Tissue Oncology Society Annual Meeting, Berlin, Germany, October 2014.
Hill-Kayser CE, Bagatell R, Reilly A, Womer R, Balamuth N, Both S, Lustig R, Tochner Z: Outcomes after proton therapy for pediatric patients with cancers of the head and neck region. American Society for Radiation Oncology Annual Meeting, Louisville, KY, May 2013.
Awards and Honors
2005, Faculty Honor Roll, Pediatric House Staff, The Children’s Hospital of Philadelphia
2001-2002, 2005-2006, 2008-2009, 2011-2015, Listed in Best Doctors in America
1985-1988, National Cancer Institute Clinical Investigator Award, 1KO8 CA-01026
1982-1984, American Cancer Society Clinical Fellowship
Editorial and Academic Positions
Academic and Institutional Committees
2014-present, Clinical Informatics Council
2012-present, Formulary Committee, Medical Staff
2012-present, Specialists with Advanced Technical Training (SWATT) Team, Department of Pediatrics
2011-present, Drug Use Evaluation Committee, Medical Staff
2009-present, Lead Medical Clinical Champion, Epic/Beacon Oncology Project
2009-present, Pediatric Proton Triage Committee
2005-present, Therapeutic Standards Committee
2002-present, Clinical Decision Support Committee, chair
1999-present, Information Services Committee, Medical Staff
Leadership and Memberships
Memberships in Professional Organizations
American Academy of Pediatrics
American Society of Clinical Oncology
Connective Tissue Oncology Society
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.